Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Glenmark Generics has received the US Food and Drug Administration (FDA) approval for its abbreviated new drug application (ANDA) of Nizatidine Capsules.
Subscribe to our email newsletter
Nizatidine is indicated for the treatment for gastric and duodenal ulcers.
It blocks one of the chemicals (histamine) that stimulates the production of stomach acid.
Following the approval, Glenmark Generics, a subsidiary of Glenmark Pharmaceuticals, expects to begin marketing of the drug soon.